Products with Hepatoprotective bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN2639 | Juglone |
| Juglone has anti-inflammatory, and anti-cancer activities, it can significantly inhibit the proliferation and induce the apoptosis of SiHa cells and Caski cells; it prevents high-fat diet-induced liver injury and nerve inflammation in mice through inhibition of inflammatory cytokine secretion, NF-kappa B activation and endotoxin production. Juglone stimulates suicidal erythrocyte death or eryptosis at least in part by upregulation of ceramide abundance, energy depletion and activation of PKC. | |
| BCN2651 | Berberrubine |
| Berberrubine possesses diverse pharmacological activities, including glucose-lowering, lipid-lowering, anti-inflammatory, and anti-tumor effects. Berberrubine dose-dependently inhibits IL-8 and MCP-1 protein levels in the media and mRNA expression of the cells stimulated with IL-1beta or TNF-alpha. | |
| BCN2653 | Phillygenin |
| Phillyrin, (+)-Phillygenin, and (-)-phillygenin exert the strongest inhibitory activities on NO production with IC(50) values. | |
| BCN2665 | Acetylshikonin |
| Acetylshikonin has anti-cancer and anti-inflammatory activity, it is a novel general P450 inhibitor with IC50 values of 1.4-4.0 μM for all tested P450s. Acetylshikonin exhibits weak cytotoxicity against human umbilical vein endothelial cells (HUVECs) with IC50 of over 20 microM, exhibits the antiangiogenic and antitumorigenic effects by suppressing proliferation and angiogenic factors. Certain shikonin derivatives(such as Acetylshikonin) act as modulators of the Nur77-mediated apoptotic pathway. | |
| BCN2668 | Cistanoside A |
| 1. Cistanoside A possesses protective activities on CCl4 induced hepatotoxicity in mice, which is involved with increasing free radicals clearing activities, alleviating lipid-overoxidation damage, and improving respiratory chain function in mitochondria. | |
